International Clinical Trial: Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07513324) titled 'Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)' on April 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Dana-Farber Cancer Institute

Condition: HPV-positive Oropharyngeal Squamous Cell Carcinoma Oropharyngeal Squamous Cell Carcinoma

Intervention: Drug: Pembroluzimab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: May 1, 2026

Target Sample Size: 116

Countries of Recruitment...